Marinus Pharmaceuticals Inc (NASDAQ: MRNS) stock suffered a major decline of -14.1% on 11/9/23. The shares closed at $5.93. The stock has been strong relative to the market over the last nine months but has declined -10.6% during the last week.
Current PriceTarget Research Rating
MRNS is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Marinus Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Marinus Pharmaceuticals has a poor Appreciation Score of 21 but a good Power Rating of 71, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment